Clinical trials for anti-cancer drugs developed by R-Pharm Group are currently underway at the University Clinical Hospital No. 1, affiliated with Sechenov University. The Center, established through university and pharmaceutical collaboration in late 2022, focuses on developing and testing Russian oncological drugs.
During the first year of the Center’s operation, four CTs were initiated, one of which has already been successfully completed. An immunotherapeutic drug for metastatic melanoma has received a registration certificate and is now in clinical practice.
“Currently, we are continuing to study three more targeted drugs that act on targets in tumor cells in gastric cancer, squamous cell carcinoma of the head and neck organs, and breast cancer. Studies of these drugs may be completed by the end of 2025,” said Marina Sekacheva, chief researcher at the Center.
